quetiapine monotherapy in acute phase for major depressive disorder a meta-analysis of randomized, placebo-controlled trials在急性期,单用奎硫平重度抑郁症的荟萃分析随机、安慰剂对照试验.pdfVIP

Maneeton et al. BMC Psychiatry 2012, 12:160 /1471-244X/12/160 RESEARCH ARTICLE Open Access Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials 1 1* 1 2 Narong Maneeton , Benchalak Maneeton , Manit Srisurapanont and Stephen D Martin Abstract Background: Schizophrenia and bipolar depression trials suggest that quetiapine may have an antidepressant effect. Objectives: This meta-analysis aimed to determine the efficacy, acceptability and tolerability of quetiapine treatment for major depressive disorder (MDD). Only the randomized controlled trials (RCTs) comparison between quetiapine and placebo were included. The authors searched such clinical trials carried out between 1991 and February 2012. Data sources: MEDLINE, EMBASE, CINHL, PsycINFO and Cochrane Controlled Trials Register were searched in February 2012. Study populations comprised adults with MDD or major depression. Study eligible criteria, participants and interventions: Eligible studies were randomized, placebo-controlled trials of quetiapine monotherapy carried out in adults with MDD and presenting endpoint outcomes relevant to: i) depression severity, ii) response rate, iii) overall discontinuation rate, or iv) discontinuation rate due to adverse events. No language restriction was applied. Study appraisal and synthesis methods: All abstracts identified by the electronic searches were examined. The full reports of relevant studies were assessed, and the data of interest were extracted. Based on the Cochrane methods of bias assessment, risks of bias were determined. The studies with two risks or less were included. The efficacy outcomes were the mea